BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
37 hedge funds and large institutions have $9.04M invested in BRAINSTORM CELL THERAPUTC in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 6 closing their positions.
67% more call options, than puts
Call options by funds: $65K | Put options by funds: $39K
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.04% less ownership
Funds ownership: 0.8% → 0.76% (-0.04%)
4% less capital invested
Capital invested by funds: $9.38M → $9.04M (-$342K)
5% less funds holding
Funds holding: 39 → 37 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$74.6K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$49.4K |
| 3 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$36K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$30.7K |
| 5 |
SPIA
Steward Partners Investment Advisory
New York
|
+$24.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$174K |
| 2 |
JP Morgan Chase
New York
|
-$107K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$91.8K |
| 4 |
Goldman Sachs
New York
|
-$54K |
| 5 |
Cerity Partners
New York
|
-$49K |
BCLI Hedge Fund Activity: Q3 2018 in Review
37 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q3 2018, worth a combined $9.04M — down 3.6% from $9.38M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BCLI and 4 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 8 added.
The largest buyer was Renaissance Technologies, adding an estimated $74.6K. The largest seller was Morgan Stanley, cutting an estimated $174K.
- 37 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q3 2018, down from 39 in Q2 2018.
- Funds reported $9.04M of BRAINSTORM CELL THERAPUTC stock for Q3 2018, down 3.6% quarter-over-quarter.
- 4 funds opened new BRAINSTORM CELL THERAPUTC positions in Q3 2018 and 6 closed out, a net change of -2 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q3 2018 was Renaissance Technologies, an estimated $74.6K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q3 2018 was Morgan Stanley, an estimated $174K sold.
Based on aggregated 13F filings for Q3 2018.